ArticleActa pharmaceutica Sinica. B2022
"Pincer movement": Reversing cisplatin resistance based on simultaneous glutathione depletion and glutathione
Article in Acta pharmaceutica Sinica. B, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 36 citations in OpenAlex.
- Sulfhydryl Sulfobetaine Stabilized Palladium Nanoparticles with High Peroxidase-like Activity for Enhanced Glutathione Detection and Tumor Suppression.Biomolecules · 2026Article
- Article
- Rapid synthesis of redox-responsive trithiocyanuric acid-based nanocarriers: in vitro multidrug resistance reversal and in vivo safety assessment.Drug delivery and translational research · 2026Article
- Autophagy initiation inhibition combined with chemotherapy reverses drug resistance in oral cancer.Discover oncology · 2026Review
- Advances in the applications of stimulus-responsive nanomedicines for anti-cancer therapy.Nanomedicine (London, England) · 2026Review
- Progress in peptide and protein therapeutics: Challenges and strategies.Acta pharmaceutica Sinica. B · 2025Review
- Article
- Engineered biomimetic cisplatin-polyphenol nanocomplex for chemo-immunotherapy of glioblastoma by inducing pyroptosis.Journal of nanobiotechnology · 2025Article
- AKR1C1 interacts with STAT3 to increase intracellular glutathione and confers resistance to oxaliplatin in colorectal cancer.Acta pharmaceutica Sinica. B · 2024Article
- Review and Future Perspectives of Stimuli-Responsive Bridged Polysilsesquioxanes in Controlled Release Applications.Polymers · 2024Review
- Natural products for enhancing the sensitivity or decreasing the adverse effects of anticancer drugs through regulating the redox balance.Chinese medicine · 2024Review
- Rapid discovery of a novel "green" and natural GST inhibitor for sensitizing hepatocellular carcinoma to Cisplatin by visual screening strategy.Journal of pharmaceutical analysis · 2024Article
- Emerging Trends in Hybrid Nanoparticles: Revolutionary Advances and Promising Biomedical Applications.Current drug metabolism · 2024Review
- Ethacrynic Acid: A Promising Candidate for Drug Repurposing as an Anticancer Agent.International journal of molecular sciences · 2023Review
- NIR light-activatable dissolving microneedle system for melanoma ablation enabled by a combination of ROS-responsive chemotherapy and phototherapy.Journal of nanobiotechnology · 2023Article
- Supplementation of Polymeric Reservoirs with Redox-Responsive Metallic Nanoparticles as a New Concept for the Smart Delivery of Insulin in Diabetes.Materials (Basel, Switzerland) · 2023Article
- Emerging nanotechnology-based therapeutics to combat multidrug-resistant cancer.Journal of nanobiotechnology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The therapeutic efficacy of cisplatin has been restricted by drug resistance of cancers. Intracellular glutathione (GSH) detoxification of cisplatin under the catalysis of glutathione
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.